SELP and cancer: There appears to be emerging evidence for primary thromboprophylaxis, based on risk assessment with biomarker screening including P-selectin, CRP, factor VIII, prothrombin F 1 + 2, and TF-bearing microparticle levels in patients with cancer, but these are not yet validated [130].